Bio News
The US Food and Drug Administration (FDA) has granted Aptitude’s next-generation Metrics COVID-19 diagnostic device its first 510(k) clearance.
The diagnostic device is three times more sensitive than existing products authorized for emergency use, and results are available 30% faster.
Aptitude is also undergoing FDA review for its Metrics COVID-19 and influenza multiplex diagnostic device.
Biobook Team
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
